Comparison of the ocular hypotensive effects of bimatoprost and timolol-dorzolamide combination in patients with elevated intraocular pressure: a 6-month study.

Abstract

PURPOSE:

To compare the ocular hypotensive efficacy and safety of topical bimatoprost and timolol-dorzolamide combination in patients with primary open-angle glaucoma (POAG) or ocular hypertension during 6 months of treatment.

METHODS:

A sample of 65 patients with a diagnosis of POAG or ocular hypertension were randomized to receive either bimatoprost 0.03% once daily or timolol-dorzolamide combination twice daily. Study visits occurred at baseline and after 2 weeks and 1, 3 and 6 months of therapy. Intraocular pressure (IOP) measurements were performed at 12.00 hours at all study visits and also at 08.00 hours and 16.00 hours at baseline and 6-month visits. At each visit, local and systemic side-effects that occurred during the treatment period were recorded. Student's t-test was used to compare the differences between IOP values.

RESULTS:

Differences in IOP between the bimatoprost and timolol-dorzolamide groups were statistically insignificant at all study visits (p > 0.05). In the bimatoprost-treated group, the IOP reduction was 6.2 +/- 1.8 mmHg, whereas it was 6.5 +/- 2.3 mmHg in the timolol-dorzolamide group after 6 months of treatment. The difference was not statistically significant (p = 0.48).

CONCLUSIONS:

The IOP-lowering efficacies of bimatoprost and timolol-dorzolamide combination were similar over a 6-month follow-up. Both bimatoprost and the timolol-dorzolamide combination were well tolerated. Bimatoprost can be used as a longterm monotherapy agent in the treatment of POAG and ocular hypertension.

• Authors: Faruk Ozturk, Sitki Samet Ermis, Umit Ubeyt Inan
• Journal: Acta ophthalmologica Scandinavica (Acta Ophthalmol Scand) Vol. 85 Issue 1 Pg. 80-3 (Feb 2007) ISSN: 1395-3907 [Print] Denmark
• PMID: 17244215 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Amides
• Antihypertensive Agents
• Lipids
• Sulfonamides
• Thiophenes
• Cloprostenol
• Timolol
• dorzolamide
• Bimatoprost

Topics

• Aged
• Amides (adverse effects, therapeutic use)
• Antihypertensive Agents (adverse effects, therapeutic use)
• Bimatoprost
• Cloprostenol (adverse effects, analogs & derivatives, therapeutic use)
• Drug Therapy, Combination
• Female
• Glaucoma, Open-Angle (drug therapy)
• Humans
• Intraocular Pressure (drug effects)
• Lipids (adverse effects, therapeutic use)
• Male
• Middle Aged
• Ocular Hypertension (drug therapy)
• Prospective Studies
• Single-Blind Method
• Sulfonamides (adverse effects, therapeutic use)
• Thiophenes (adverse effects, therapeutic use)
• Timolol (adverse effects, therapeutic use)